{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:17:39Z","timestamp":1649193459538},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T00:00:00Z","timestamp":1268265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s00105-009-1902-2","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T16:32:36Z","timestamp":1268152356000},"page":"976-979","source":"Crossref","is-referenced-by-count":1,"title":["Prim\u00e4r nodales follikul\u00e4res Lymphom mit sekund\u00e4rer kutaner Manifestation"],"prefix":"10.1007","volume":"61","author":[{"given":"R.","family":"Koch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,3,11]]},"reference":[{"key":"1902_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N et al (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101\u2013106","journal-title":"Blood"},{"key":"1902_CR2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"1902_CR3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","volume":"155","author":"Kerl","year":"2006","unstructured":"Kerl K, Prins C, Saurat JH, French LE (2006) Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 155:1197\u20131200","journal-title":"Br J Dermatol"},{"key":"1902_CR4","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1055\/s-0028-1091252","volume":"133","author":"Fridrik","year":"2008","unstructured":"Fridrik MA (2008) Maligne Lymphome im Erwachsenenalter. Dtsch Med Wochenschr 133:2109\u20132114","journal-title":"Dtsch Med Wochenschr"},{"key":"1902_CR5","first-page":"481","volume":"108","author":"Marcus","year":"2006","unstructured":"Marcus RE, Solal-Celigny P, Imrie K et al (2006) MabThera (rituximab) plus cyclophosphamide, vincristine and prednisone (CVP) chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin\u2019s lymphoma. Blood ASH Annu Meet 108:481","journal-title":"Blood ASH Annu Meet"},{"key":"1902_CR6","first-page":"79","volume":"26","author":"McLaughlin","year":"1999","unstructured":"McLaughlin P, Hagemeister FB, Grillo-Lopez AJ (1999) Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26(5 Suppl 14):79\u201387","journal-title":"Semin Oncol"},{"key":"1902_CR7","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.22649","volume":"109","author":"Sacchi","year":"2007","unstructured":"Sacchi S, Pozzi S, Marcheselli L et al (2007) Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 109:2077\u20132082","journal-title":"Cancer"},{"key":"1902_CR8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P, White J et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265","journal-title":"Blood"},{"key":"1902_CR9","first-page":"585","volume":"104","author":"Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Salles GA, Brousse N et al (2004) Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma: survival analyses with a follow-up of at least years. Blood ASH Annu Meet 104:585","journal-title":"Blood ASH Annu Meet"},{"key":"1902_CR10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2005.12.052","volume":"23","author":"Witzig","year":"2005","unstructured":"Witzig TE, Vukov AM, Habermann TM et al (2005) Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin\u2019s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:1103\u20131108","journal-title":"J Clin Oncol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-009-1902-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-009-1902-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-009-1902-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:46Z","timestamp":1558582666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-009-1902-2"}},"subtitle":["First-line-Rituximab-Monotherapie"],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1902"],"URL":"https:\/\/doi.org\/10.1007\/s00105-009-1902-2","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,11]]}}}